Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

506581

registered interest
date	08/04/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the average cost of treating a patient with (a) hepatitis C, (b) cirrhosis and (c) hepatitis C and cirrhosis has been in the last 12 months for which figures are available.
tabling member constituency	Corby
tabling member printed	Tom Pursglove
uin	32899
answer	answer is ministerial correction date of answer 18/04/2016 answer text <p><strong> </strong></p><p>The information is not available in the format requested. Such information as is available is shown in the table below and is from reference costs, which are the average unit cost to National Health Service trusts and foundation trusts of providing defined services in a given financial year. Reference costs are published annually, with most recently available data being for 2014-15.</p><p> </p><p>Reference costs for acute care are collected by healthcare resource group (HRG), which are standard groupings of clinically similar treatments that consume similar levels of healthcare resource. HRGs are organised by chapters and sub-chapters, representing different body systems, and HRG sub-chapters GC and PG describe hepatobiliary and pancreatic system disorders for adults and children respectively. The average costs in the following table will therefore include the costs to NHS hospitals of treating hepatitis C and cirrhosis, as well as the costs of other related disorders.</p><p> </p><p>These costs do not include high cost drugs, or treatment in outpatient or other settings outside of hospital. They reflect the costs of a single episode of care under one consultant for a patient admitted to hospital. Patients admitted to hospital may have multiple episodes of care and each one of these episodes will be recorded separately.</p><p> </p><p> </p><p>Table: Average cost to NHS hospitals of treating hepatobiliary and pancreatic system disorders, 2014-15 (excluding high cost drugs, or treatment in outpatient or other settings outside of hospital)</p><table><tbody><tr><td><p> </p></td><td><p>Average cost per unit of activity (£)</p></td></tr><tr><td><p>Non-Malignant, Hepatobiliary or Pancreatic Disorders</p></td><td><p>1,751</p></td></tr><tr><td><p>Paediatric, Hepatobiliary or Pancreatic Disorders</p></td><td><p>2,344</p></td></tr></tbody></table><p><em>Source: </em>Reference costs, Department of Health</p><p> </p><p><em>Notes:</em></p><ol><li>The following HRGs are included in the table:</li></ol><p>GC17A Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 9+</p><p>GC17B Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 4-8</p><p>GC17C Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 0-3</p><p>GC17D Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 9+</p><p>GC17E Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 4-8</p><p>GC17F Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 0-3</p><p>GC17G Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 8+</p><p>GC17H Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 5-7</p><p>GC17J Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 2-4</p><p>GC17K Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 0-1</p><p>PG71A Paediatric, Hepatobiliary or Pancreatic Disorders, with CC Score 2+</p><p>PG71B Paediatric, Hepatobiliary or Pancreatic Disorders, with CC Score 1</p><p>PG71C Paediatric, Hepatobiliary or Pancreatic Disorders, with CC Score 0</p><ol start="2"><li>These HRGs are common groupings of the ICD-10 codes used to count the number of finished admission episodes with a primary or secondary diagnosis of hepatitis C or cirrhosis. They also include other ICD-10 codes.</li><li>For each HRG or other currency in the reference cost collection, NHS hospital trusts submit a unit cost and amount of activity undertaken.</li></ol><p><strong> </strong></p> answering member constituency Battersea answering member printed Jane Ellison question first answered 18/04/2016 16:43:27 answering member 3918 label Biography information for Jane Ellison
tabling member	4369 label Biography information for Tom Pursglove

456168

registered interest
date	29/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many hospital admissions due to liver disease there were in (a) England and (b) each parliamentary constituency in the last year for which figures are available.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	28830
answer	answer is ministerial correction date of answer 08/03/2016 answer text <p>The information requested is in the attached table.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/03/2016 16:43:04 answering member 3918 label Biography information for Jane Ellison attachment 1 file name PQ28830 TABLE.xlsx title Finished admission episodes liver disease
tabling member	4051 label Biography information for John Glen

456170

registered interest
date	29/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the total cost of treating liver disease was in (a) England and (b) each parliamentary constituency in the last year for which figures are available.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	28829
answer	answer is ministerial correction date of answer 07/03/2016 answer text <p>Information on the total cost of treating liver disease in England and in each parliamentary constituency is not available centrally.</p><p> </p><p>Such information as is available is from reference costs, which are the average unit cost to National Health Service hospital trusts of providing defined services to patients in a given financial year. Reference costs for acute care are collected by Healthcare Resource Group (HRG), which are standard groupings of similar treatments that use similar resources. HRGs are organised by chapters and sub-chapters, representing different body systems, and HRG sub-chapter GC describes hepatobiliary and pancreatic system disorders. The total costs in the following table, calculated from the national average unit costs and activity submitted in reference costs, will therefore include the costs to NHS hospitals of treating liver and liver related diseases, but also the costs of other related disorders.</p><p> </p><p>Estimated total costs (£ millions) to NHS hospitals of treating hepatobiliary and pancreatic system disorders, 2014-15</p><table><tbody><tr><td><p>Liver failure disorders</p></td><td><p>£17.7 million</p></td></tr><tr><td><p>Malignant, hepatobiliary or pancreatic disorders</p></td><td><p>£54.3 million</p></td></tr><tr><td><p>Non-malignant, hepatobiliary or pancreatic disorders</p></td><td><p>£328.1 million</p></td></tr><tr><td><p>Total costs</p></td><td><p>£400.0 million</p></td></tr></tbody></table><p><em>Source</em>: reference costs, Department of Health</p><p> </p><p><em>Notes:</em></p><ol><li>The following HRGs are included in the table:</li></ol><p>Liver Failure Disorders with Multiple Interventions</p><p>Liver Failure Disorders with Single Intervention</p><p>Liver Failure Disorders without Interventions, with CC (Complication and Comorbidity) Score 5+</p><p>Liver Failure Disorders without Interventions, with CC Score 0-4</p><p>Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions</p><p>Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 5+</p><p>Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 2-4</p><p>Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 0-1</p><p>Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 6+</p><p>Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 3-5</p><p>Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 1-2</p><p>Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 0</p><p>Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 9+</p><p>Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 4-8</p><p>Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 0-3</p><p>Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 9+</p><p>Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 4-8</p><p>Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 0-3</p><p>Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 8+</p><p>Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 5-7</p><p>Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 2-4</p><p>Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 0-1</p><p> </p><ol start="2"><li>These HRGs are common groupings of the International Classification of Disease (ICD-10) codes used to count the number of finished admission episodes with a primary or secondary diagnosis of liver disease or liver related disease. They also include other ICD-10 codes.</li></ol><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Battersea answering member printed Jane Ellison question first answered 07/03/2016 16:21:09 answering member 3918 label Biography information for Jane Ellison
tabling member	4051 label Biography information for John Glen

451288

registered interest
date	08/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the potential future savings to the public purse of reducing (a) hepatitis C related end-stage liver disease and (c) liver cancer.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	26348
answer	answer is ministerial correction date of answer 16/02/2016 answer text <p>No such formal assessment has been made, although the potential benefits of new treatments becoming available are widely recognised.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 16/02/2016 13:59:32 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon

438962

registered interest
date	16/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much has been spent on NHS England's commissioning policy for the treatment of cirrhosis in adults with hepatitis C.
tabling member constituency	Oxford East
tabling member printed	Mr Andrew Smith
uin	20471
answer	answer is ministerial correction date of answer 11/01/2016 answer text <p>NHS England is not in a position to confirm spend to date on the treatment of cirrhosis in adults with hepatitis C. The overall spend will be impacted by the commercial in confidence agreements that are in place with a number of pharmaceutical companies as well as confirmation that patients treated have completed their course. NHS England will be in a position to confirm overall spend on hepatitis C as a result of the commissioning policy and National Institute for Health and Care Excellence guidance at the end of the financial year.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 11/01/2016 18:04:02 answering member 3918 label Biography information for Jane Ellison
tabling member	95 label Biography information for Mr Andrew Smith

425127

registered interest
date	30/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the recommendations of the Lancet Commission on liver disease, published in November 2014.
tabling member constituency	East Ham
tabling member printed	Stephen Timms
uin	14170
answer	answer is ministerial correction date of answer 04/11/2015 answer text <p>NHS England is responsible for the overall national approach to improving clinical outcomes for people with liver disease. It is adopting a broad strategy to reduce premature mortality, including mortality from liver disease, and is working jointly with stakeholders to make sure that patients with liver disease are supported. In addition, Public Health England is working with stakeholders to develop a liver disease framework and is also working closely with the Lancet Commission.</p><br /><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p> answering member constituency Battersea answering member printed Jane Ellison question first answered 04/11/2015 17:43:12 answering member 3918 label Biography information for Jane Ellison
tabling member	163 label Biography information for Sir Stephen Timms

422271

registered interest
date	19/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make an assessment of the potential of minimum unit pricing of 50 pence per unit of alcohol to improve liver disease health outcomes in England.
tabling member constituency	Oxford East
tabling member printed	Mr Andrew Smith
uin	12286
answer	answer is ministerial correction date of answer 27/10/2015 answer text <p>The 2015-16 remit letter from the Department of Health asked Public Health England to review the evidence and provide advice on the public health impacts of alcohol and possible evidence-based solutions.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 27/10/2015 15:47:38 answering member 3918 label Biography information for Jane Ellison
tabling member	95 label Biography information for Mr Andrew Smith

422279

registered interest
date	19/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many people have been diagnosed with liver disease in each of the last five years.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	12481
answer	answer is ministerial correction date of answer 27/10/2015 answer text <p>Information is not available in the format requested.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 27/10/2015 15:39:14 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon

420745

registered interest
date	12/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many people were diagnosed with primary biliary cirrhosis in each of the last five years.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	11331
answer	answer is ministerial correction date of answer 20/10/2015 answer text <p>Information is not held in the format requested.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 20/10/2015 14:55:52 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon

386476

registered interest
date	30/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government when Public Health England's programme of work on liver disease will be published.
tabling member printed	Baroness Randerson
uin	HL971
answer	answer is ministerial correction date of answer 09/07/2015 answer text <p>Public Health England’s liver disease framework will be published in autumn 2015.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 09/07/2015 12:59:16 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4230 label Biography information for Baroness Randerson